Vivos Therapeutics shares are trading higher after the company announced that it received a notice of allowance for its U.S. patent application 17/522,740 titled "Vibrational Oral Appliance With Mandibular Advancements (To Provide Relief From Sleep Disordered Breathing, Sleep Apnea And/Or Snoring)"
Portfolio Pulse from Benzinga Newsdesk
Vivos Therapeutics' shares surged following the announcement of a notice of allowance for its U.S. patent application for a device aimed at treating sleep disordered breathing, sleep apnea, and snoring.
April 04, 2024 | 4:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Vivos Therapeutics' stock price is expected to rise in the short term due to the positive news regarding its patent allowance for a sleep disorder treatment device.
The notice of allowance for Vivos Therapeutics' patent application is a significant positive development, indicating potential market exclusivity and competitive advantage for its sleep disorder treatment device. This kind of regulatory milestone typically boosts investor confidence and can lead to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100